Editas Medicine, Inc. Common Stock

EDITNASDAQ • USD
2.17 USD
↗ 0.03 (1.40%)AT CLOSE (03:59 PM EST)
2.12
↘ 0.05 (2.17%)
POST MARKET (AS OF 07:57 PM EST)
Post Market
AS OF 07:57 PM EST
2.12
↘ 0.05 (2.17%)
🔴Market: CLOSED

Editas Medicine, Inc. Common Stock (EDIT) trades at $2.17 per share. Technical and fundamental signals converge bearish — technicals rate "Strong Sell" while fundamentals read "Sell". This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 2/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. On valuation, EDIT trades roughly in line with sector averages — neither particularly cheap nor expensive.

Technical & fundamental data as of Nov 13, 2026.

Open?$2.14
High?$2.21
Low?$2.01
Prev. Close?$2.14
Volume?2.8M
Avg. Volume?2.4M
VWAP?$2.12
Rel. Volume?1.14x
Bid / Ask
Bid?$2.10 × 100
Ask?$2.15 × 100
Spread?$0.05
Midpoint?$2.13
Valuation & Ratios
Market Cap?334.9M
Shares Out?154.3M
Float?148.8M
Float %?96.9%
P/E Ratio?N/A
P/B Ratio?3.96
EPS?-$0.47
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
Employees
87
Market Cap
334.9M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed
2016-02-03
Address
11 HURLEY ST.
CAMBRIDGE, MA 02141
Phone: 617-401-9000
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-3/3)
Medium-Term (Wave)?▼ Bearish(-2/3)
Short-Term (Ripple)?▼ Bearish(-2/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
12
Z-Score?
0
Momentum?
50
Short Sent.?
10
Piotroski F-Score?2/9Weak
Altman Z-Score?-9.52Distress
Confidence?63%Moderate
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?26.02%Squeeze Risk
Short Interest?38.7M
Days to Cover?17.6
Free Float148.8M
Avg Daily Volume2.2M
Settlement Date2026-10-30
Financial Health
Current Ratio?2.82Strong
Quick Ratio?2.82Strong
Cash Ratio?1.30Strong
Debt/Equity?0.67Moderate
ValuationFAIRLY VALUEDvs 3 peers + S&P 500
Score
75/100
P/E?
N/A▾
P/B?
Peers
25
S&P
45
3.96FAIR▾
P/S?
Peers
100
S&P
18
6.72FAIR▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-3.7CHEAP▾
EV/Sales?
Peers
100
S&P
28
5.99FAIR▾
Returns & Efficiency
ROE?
S&P
3
-85.5%WEAK▾
ROA?
S&P
3
-32.9%WEAK▾
Cash Flow & Enterprise
FCF?$-110464000
Enterprise Value?$298.6M
Fundamentals ratios updated end of day